AlphaGen
Access AlphaGen
Company Narratives

Macter International FY26: Gross Margins Expand, but Tax and Working Capital Dilute the Gain

Macter’s FY26 revenue and gross margin improved, but higher commercial costs, a sharply heavier tax burden and weaker cash conversion pulled consolidated earnings lower.

Sep 23, 2026

Verdict

Macter International Limited closed FY26 with a stronger top line and materially better gross profitability, but those gains did not fully reach shareholders. On a consolidated basis, revenue rose 17.5% to Rs12.17 billion and gross profit rose 25.2% to Rs5.92 billion, lifting gross margin to 48.6% from 45.6%. Yet selling and distribution expenses and administrative expenses grew roughly 30%, operating margin slipped, finance cost edged higher and income tax expense rose 57.6%. Consolidated profit after tax therefore fell 14.2% to Rs675.2 million, while EPS declined to Rs14.83 from Rs16.95.

The fourth-quarter bridge makes the tension clearer. Derived by subtracting the officially reported nine-month March 2026 figures from the full-year June 2026 result, Q4 consolidated revenue grew about 8.0% year on year and gross margin improved to 48.7% from 46.1%. But selling and distribution expense grew about 25%, operating profit fell 15.5%, finance cost rose 29.4%, and tax expense more than doubled. Derived Q4 PAT consequently fell about 51% to Rs145.9 million. The company still has a healthy gross-profit engine; the pressure has shifted below gross profit into commercial spending, funding and tax.

Company and reporting basis

Company Name: Macter International Limited

Ticker: MACTER

Reporting period: year ended June 30, 2026, with a derived Q4 comparison based on the full-year result less the official nine-month results for March 31, 2026.

Reporting basis: this article uses the consolidated group result as the primary analytical basis and refers to the unconsolidated parent result where useful. The group comprises Macter International Limited and its subsidiary, Misbah Cosmetics (Private) Limited. The March interim report identifies Macter as a pharmaceutical manufacturer and Misbah Cosmetics as a cosmetics selling and distribution business.

The Board considered the FY26 result on September 22, 2026 and the company filed the result with PSX on September 23. The filing says the Annual Financial Statements/Annual Report will be transmitted separately before the October 28 AGM. The result release itself does not include an independent auditor’s report, so this article does not infer or characterize the FY26 audit opinion.

AlphaGen model outputs

Alpha QoQ Score: 37.15

TTM Performance Score: 28.11

3Y Business Perf Score: 81.16

Sector Leadership Score: 35.7446

These four scores are AlphaGen model outputs, not company-reported figures.

Results at a glance

  • Consolidated FY26 revenue: Rs12.17 billion, up 17.5%.
  • Gross profit: Rs5.92 billion, up 25.2%; gross margin expanded to 48.6% from 45.6%.
  • Operating profit: Rs1.38 billion, up 8.2%, but operating margin slipped to 11.3% from 12.3%.
  • Profit before tax: Rs1.234 billion, up 8.1%.
  • Income tax: Rs558.8 million, up 57.6%, taking the effective tax burden to roughly 45.3% of PBT versus 31.1% a year earlier.
  • Consolidated PAT: Rs675.2 million, down 14.2%; EPS: Rs14.83 versus Rs16.95.
  • Operating cash flow: Rs388.5 million, down 32.0%.
  • Trade receivables: Rs1.236 billion, up about 143%; inventory: Rs3.053 billion, up 15.3%.
  • Cash and bank balances: Rs109.8 million, down from Rs288.6 million.
  • No FY26 cash dividend, bonus or rights issue was recommended.
  • Separately, the Board proposed a 5-for-1 subdivision of the shares, reducing face value from Rs10 to Rs2, subject to shareholder and regulatory approvals. Paid-up capital does not change.

What improved

The clearest improvement is at the gross-profit line. Consolidated revenue increased by Rs1.81 billion, while cost of sales rose only 10.9%. That allowed gross profit to rise by Rs1.19 billion and expanded the gross margin by about 3.0 percentage points. The same direction was visible earlier in FY26. In its March corporate briefing covering H1FY26, management said sales growth was supported by expansion of the local portfolio, new launches in niche and low-competition segments and higher export volumes; it also attributed the H1 gross-margin improvement to better sales mix and higher contribution from prescription and export business. That explanation is useful context, but the year-end result does not provide a product-by-product or geography-by-geography bridge, so it is not possible to quantify how much of FY26 growth came from price, volume, mix or individual launches.

One important operating development during the year was the January launch of TirzaTrim, Macter’s tirzepatide multidose pre-filled pen. The company presented the launch as an expansion of its biotechnology and advanced injectable portfolio. It is reasonable to treat this as part of the portfolio-development story, but not as a quantified earnings driver because the company has not disclosed sales or margin contribution from the product.

Macter’s revenue growth also outpaced the broader physical-output backdrop. PBS’s latest industry table reports only modest FY25-26 growth in pharmaceutical production and a sharp year-on-year contraction in July 2026. That does not prove market-share gains or pricing power—Macter’s revenue includes mix and price effects while the PBS series measures production—but it shows that a 17.5% revenue increase cannot simply be explained by broad sector output growth.

What weakened / needs attention

The main weakness is operating leverage below gross profit. Selling and distribution expense rose 29.8% to Rs3.59 billion and administrative expense increased 30.2% to Rs883.5 million. Together they grew much faster than revenue. As a result, operating profit increased only 8.2% even though gross profit grew 25.2%, and the operating margin compressed by roughly one percentage point.

This pattern was especially visible in the derived fourth quarter. Q4 revenue was about Rs2.895 billion, up 8.0% from the comparable quarter, and gross profit was about Rs1.409 billion, up 13.9%. Yet selling and distribution expense rose 24.9%, administrative expense rose 14.9%, and operating profit fell 15.5% to roughly Rs338.5 million. Gross economics remained constructive; commercialization and overhead absorbed the incremental gross profit.

A same-calendar-quarter peer check suggests at least part of the commercial-cost pressure was not unique to Macter. Highnoon Laboratories’ official consolidated April-June 2026 result showed revenue growth of about 4.9% and gross-profit growth of about 3.1%, while distribution, selling and promotional expense rose about 18.4% and operating profit fell about 19.8%. The comparison is directional rather than like-for-like because the companies have different product portfolios and reporting structures, but both show that sales growth in the quarter did not automatically translate into stronger operating profit.

Tax was the bigger differentiator. Macter’s consolidated income-tax expense rose to Rs558.8 million from Rs354.4 million while PBT rose only 8.1%. The implied effective tax burden increased to about 45.3% from 31.1%. In the derived Q4 alone, tax expense was roughly Rs145.3 million, more than twice the comparable quarter, while PBT fell about 20%. The result filing does not explain the increase in enough detail to attribute it to a specific tax rule, prior-year adjustment or deferred-tax movement, so assigning a precise cause would be speculative. The economic conclusion is simpler: tax absorbed more than all of the pre-tax earnings growth.

Highnoon’s comparable quarter did not show the same tax direction—its tax expense declined—so the Macter tax swing should not be treated as a universal pharmaceutical-sector outcome. It needs company-specific explanation in the full annual report.

Cash conversion and working capital

Cash conversion weakened despite profitable growth. Consolidated cash generated from operations before financing charges, tax and other listed adjustments was Rs1.054 billion, slightly below Rs1.118 billion a year earlier. After those outflows, net cash from operating activities fell 32.0% to Rs388.5 million. Tax paid rose to Rs521.5 million from Rs343.5 million and financial charges paid increased to Rs132.6 million from Rs106.7 million.

The balance sheet shows where more capital became tied up. Trade debts jumped to Rs1.236 billion from Rs508.6 million, an increase of roughly 143%. Inventory rose 15.3% to Rs3.053 billion. Trade and other liabilities also increased, to Rs2.070 billion from Rs1.593 billion, which partly financed the working-capital build, but did not prevent cash from falling to Rs109.8 million from Rs288.6 million.

This does not indicate an immediate liquidity break: consolidated current assets of Rs4.881 billion still exceeded current liabilities of Rs2.734 billion. But the quality of growth is weaker when receivables rise much faster than sales and operating cash flow falls while reported revenue expands. The next annual report should clarify customer concentration, ageing, credit terms and whether the receivable build normalizes after year-end.

Investment continued. The group spent about Rs689.7 million on additions to property, plant and equipment during FY26, below Rs872.3 million in FY25 but still substantial relative to operating cash generation. Net investing cash outflow was Rs660.3 million. Funding therefore remained important: short-term borrowings ended at Rs290.7 million versus Rs169.9 million a year earlier, while long-term financing and its current portion also increased. Finance cost rose 8.9% to Rs146.6 million.

Parent versus consolidated result

The unconsolidated parent generated FY26 revenue of Rs11.732 billion, up 18.3%, and PAT of Rs698.3 million, down 5.3%. Consolidated PAT was lower at Rs675.2 million. It would be incorrect to equate that difference directly with the standalone loss of the subsidiary because consolidation also includes eliminations and non-controlling interests. What can be said safely is that the consolidated group outcome was weaker than the parent-only outcome, making subsidiary and elimination detail worth reviewing when the full annual report is published.

Recurring versus non-recurring earnings

The strongest recurring feature is revenue and gross-margin progress. It was visible through H1, nine months and the full year, and management linked the H1 improvement to portfolio mix, prescription/export contribution and new launches. The weaker operating conversion also appears recurring enough to monitor because selling/distribution and administration grew faster than revenue for the full year and in derived Q4.

The tax jump is material but its recurrence is uncertain until the annual tax note is available. It should not be normalized away, because it is part of reported earnings, but it also should not automatically be extrapolated at the FY26 effective rate without understanding the components.

The share subdivision is a capital-structure presentation change, not an operating earnings event. If approved and implemented, the number of shares will increase fivefold and face value per share will fall from Rs10 to Rs2 without changing total paid-up capital. Per-share historical comparisons will need appropriate split adjustment.

Historical perspective

Macter’s parent-company revenue has risen from about Rs5.31 billion in FY22 to Rs6.68 billion in FY23, Rs7.54 billion in FY24, Rs9.91 billion in FY25 and Rs11.73 billion in FY26. FY25 had marked a particularly strong earnings step-up, with parent PAT reaching Rs737.5 million. FY26 therefore does not represent a reversal of the multi-year sales expansion; it represents a deterioration in earnings conversion after a strong prior year.

That distinction matters. The company is selling substantially more and earning a higher gross margin, but the incremental gross profit is being consumed by selling costs, administration, financing and—most visibly in FY26—tax. The next phase of the story depends less on proving demand and more on converting that demand into operating and free cash earnings.

Corporate actions and current risk flags

The Board recommended no cash dividend, bonus shares, rights issue or other entitlement with the FY26 result. On the same day, Macter separately disclosed the proposed 5-for-1 share subdivision, subject to approvals.

PSX currently also displays a Risk Warning Alert on Macter’s company page stating that the company is in continuous violation under clauses 5.11.1 or 5.11.2 and carries suspension or delisting risk. The PSX page does not explain the specific underlying breach in the warning text shown there, so it would be inappropriate to infer the cause. The status itself is material and should be monitored until PSX removes or clarifies it.

What to monitor next

First, the full FY26 annual report and tax note. The most important unresolved accounting question is why the effective tax burden rose so sharply and how much is current, prior-year, deferred or otherwise non-recurring.

Second, receivables and cash conversion. Trade debts rose far faster than revenue. A reversal would materially improve earnings quality; continued build would increase financing needs.

Third, selling and distribution efficiency. FY26 gross margin improved, but operating margin did not. The key test is whether new launches and wider commercial reach can scale without selling costs continuing to outgrow sales.

Fourth, product and mix progression. TirzaTrim and other niche launches broaden the portfolio, but future disclosures need to show whether they lift sustainable revenue and margin rather than simply expand the cost base.

Fifth, debt and finance cost. Short-term borrowing increased and cash fell. Even with current assets covering current liabilities, the balance sheet is more funding-intensive than a year ago.

Sixth, the share subdivision and PSX risk-warning status. The split changes per-share presentation rather than intrinsic operations, while any unresolved listing-compliance issue is a separate governance and market-access risk.

The FY26 result therefore leaves a clear two-sided picture: Macter’s sales engine and gross margin are stronger, but operating expense, working capital and tax have become the constraints. The next result cycle needs to show that higher revenue can convert into operating profit, cash and after-tax earnings rather than stopping at the gross-profit line.

Sources

Explore more research

All articles